Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Canan Karan"'
Autor:
Atike Gökçen Demiray, Aydın Demiray, Arzu Yaren, Burcu Taşköylü, Gamze Gököz Doğu, Serkan Değirmencioğlu, Umut Çakıroğlu, Nail Özhan, Canan Karan, Burçin Çakan Demirel, Tolga Doğan, Melek Özdemir
Publikováno v:
The Turkish Journal of Gastroenterology, Vol 33, Iss 8, Pp 696-703 (2022)
Externí odkaz:
https://doaj.org/article/161a9eb498124b999615efef94d858c9
Autor:
Atike Gökçen Demiray, Arzu Yaren, Uğur Sungurtekin, Papatya Bahar Baltalarlı, Neşe Demirkan, Duygu Herek, Burcu Yapar Taşköylü, Gamze Gököz Doğu, Serkan Değirmencioğlu, Utku Özgen, Halil Sağınç, Umut Çakıroğlu, Nail Özhan, Canan Karan, Burçin Çakan Demirel, Tolga Doğan, Melek Özdemir
Publikováno v:
Journal of Oncology. 2022:1-8
Aim. The current standard treatment of locally advanced rectal carcinoma is total mesorectal excision and postoperative adjuvant chemotherapy after neoadjuvant concurrent chemoradiotherapy (NCRT). Many studies have shown that pathological complete re
Autor:
canan karan
Publikováno v:
Eurasian Journal of Medical Investigation.
Autor:
Canan Karan, Elaine Tan, Humaira Sarfraz, Todd C. Knepper, Christine M. Walko, Seth Felder, Richard Kim, Ibrahim Halil Sahin
Publikováno v:
JCO oncology practice. 18(8)
The treatment paradigm for colorectal cancer (CRC) has changed significantly over the past decade with targeted therapeutics. Human epidermal growth factor receptor 2 ( HER2) amplification is seen among 3%-4% of patients with metastatic CRC (mCRC). T
Autor:
Ola Gaber, Canan Karan, Christine Marie Walko, Todd C Knepper, Richard D. Kim, Ibrahim Halil Sahin
Publikováno v:
Journal of Clinical Oncology. 41:239-239
239 Background: The benefit of immunotherapy for patients with mCRC with high tumor mutational burden (TMB-H) has been widely debated. In 2020, the FDA approved the use of pembrolizumab for the treatment of patients with TMB-H unresectable or metasta
Autor:
Atike Gökçen, Demiray, Aydın, Demiray, Arzu, Yaren, Burcu, Yapar Taşköylü, Gamze, Gököz Doğu, Serkan, Değirmencioğlu, Umut, Çakıroğlu, Nail, Özhan, Canan, Karan, Burçin, Çakan Demirel, Tolga, Doğan, Melek, Özdemir
Background: First-line treatments for metastatic pancreatic cancer are chemotherapy regimens consisting of 5-fluorouracil or gemcitabine; however, there are no biomarkers to help determine which patients might benefit from which treatment regimens. W
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f50b3f78a5824ee343005db969330e4
https://doi.org/10.5152/tjg.2022.21829
https://doi.org/10.5152/tjg.2022.21829
Autor:
Arzu Yaren, Ferda Bir, Serkan Değirmencioğlu, Ahmet Ergin, Canan Karan, Gamze Gököz Doğu, Burcu Yapar Taskoylu, Aydın Demiray, Atike Gökçen Demiray, Hakan Akca, Umut Çakiroğlu, Nail Özhan
Publikováno v:
Journal of Oncological Sciences. 6:147-152
Objective:Apoptosis plays a critical role in carcinogenesis. Intracellular proteases known as caspase-9 directly or indirectly playroles inactivating apoptosis. In this study, we aimed to investigate the effect of caspase-9 level in lung skuamous can
Autor:
Canan Karan, Elaine Tan, Humaira Sarfraz, Christine Marie Walko, Richard D. Kim, Todd C Knepper, Ibrahim Halil Sahin
Publikováno v:
Journal of Clinical Oncology. 40:e15569-e15569
e15569 Background: Increased molecular profiling ability has resulted in the recognition of important actionable genes that can be used to direct targeted therapies in colorectal cancers (CRC). Neurotrophin receptor tyrosine kinase (NTRK) gene fusion
Autor:
Canan Karan, Elaine Tan, Humaira Sarfraz, Christine Marie Walko, Richard D. Kim, Todd C Knepper, Ibrahim Halil Sahin
Publikováno v:
Journal of Clinical Oncology. 40:e15568-e15568
e15568 Background: Next-generation sequencing (NGS) based molecular profiling technologies have revealed several oncogenic fusion genes that are actionable with small molecule inhibitors leading to practice change, particularly in lung cancer. The mo